BriaCell Therapeutics Corp. (NASDAQ:BCTX) Sees Large Drop in Short Interest

BriaCell Therapeutics Corp. (NASDAQ:BCTX) was the recipient of a large decrease in short interest in the month of November. As of November 15th, there was short interest totalling 534,800 shares, a decrease of 28.2% from the October 31st total of 745,100 shares. Approximately 1.7% of the shares of the company are sold short. Based on an average daily volume of 5,020,000 shares, the short-interest ratio is currently 0.1 days.

Hedge Funds Weigh In On BriaCell Therapeutics

An institutional investor recently bought a new position in BriaCell Therapeutics stock. Vontobel Holding Ltd. purchased a new stake in shares of BriaCell Therapeutics Corp. (NASDAQ:BCTX) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 80,000 shares of the company’s stock, valued at approximately $99,000. Vontobel Holding Ltd. owned 0.44% of BriaCell Therapeutics at the end of the most recent quarter. Institutional investors own 15.42% of the company’s stock.

BriaCell Therapeutics Trading Up 16.6 %

BriaCell Therapeutics stock traded up $0.14 during midday trading on Friday, hitting $0.98. The stock had a trading volume of 1,517,233 shares, compared to its average volume of 1,571,148. The company has a market capitalization of $35.54 million, a PE ratio of -0.84 and a beta of 1.39. BriaCell Therapeutics has a 52-week low of $0.46 and a 52-week high of $5.97. The firm’s fifty day moving average is $0.81 and its two-hundred day moving average is $0.92.

BriaCell Therapeutics (NASDAQ:BCTX) last announced its quarterly earnings results on Monday, October 28th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.45. As a group, equities research analysts predict that BriaCell Therapeutics will post -0.58 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of BriaCell Therapeutics in a research note on Thursday, October 3rd.

BriaCell Therapeutics Company Profile

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.